PrimeRFP SCOUT · Federal Contract Recompete Brief

HHSO100201700016C — EBOLA THERAPEUTICS

EBOLA THERAPEUTICS is a federal NONE award for Department of Health and Human Services (HHS) held by REGENERON PHARMACEUTICALS, INC.. Estimated value $693.1M ($0 obligated). Current period of performance ends Sep 29, 2027. Last award drew 2 bidders.

$693.1M
Estimated Value
$0
Obligated
Sep 29, 2027
PoP End / Expires
2
Bidders (last award)

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See related expiring contracts →

Analysis

Public

REGENERON PHARMACEUTICALS, INC. holds $-7,005,694 across 6 federal awards. Competition previously drew 2 offers. Set-aside status: NONE. Recompete timing centers on the Sep 29, 2027 PoP end — agencies typically plan 12–18 months ahead.

Contract facts

NONE
Contract numberHHSO100201700016C
AgencyDepartment of Health and Human Services (HHS)
IncumbentREGENERON PHARMACEUTICALS, INC.
UEIN3F9MH7E6HD6
NAICS541711

No full NAICS 541711 intel page yet. Browse NAICS intelligence

PSCAN13
PoP end (current)Sep 29, 2027
Obligated$0

Recompete timing

Public
Expiring in 408 days

Current PoP ends Sep 29, 2027 (408 days remaining). Agencies typically plan 12–18 months ahead — position before the PoP clock runs out.

Watch this contract — one email →

Incumbent footprint

Public record

REGENERON PHARMACEUTICALS, INC.$-7,005,694 obligated across 6 awards (firm-wide, all agencies).

Open full company profile

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See the recompete window for HHSO100201700016C
More in SCOUT
Track this contract →

Alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

Size up the competition →

See all live recompete landscapes — who else is expiring, and where the openings are.

Research the incumbent →

Open REGENERON PHARMACEUTICALS, INC.’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.

Frequently asked questions

What is contract HHSO100201700016C?

HHSO100201700016C (EBOLA THERAPEUTICS) is a Department of Health and Human Services (HHS) award with an estimated value of $693.1M, currently held by REGENERON PHARMACEUTICALS, INC.. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.

Who is the incumbent on HHSO100201700016C?

REGENERON PHARMACEUTICALS, INC. is the incumbent with $-7,005,694 across 6 related awards in SCOUT’s public footprint. The current period of performance ends Sep 29, 2027.

When does HHSO100201700016C come up for recompete?

SCOUT tracks a period-of-performance end of Sep 29, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/HHSO100201700016C